The following peptides represent the strongest candidates based on mechanism complementarity, safety profiles, and documented outcomes from the research community
The glycemic control program, the cardiovascular outcomes trial, and the kidney outcomes trial were all built on once-weekly administration
72-week results in adults with obesity (BMI 30), without diabetes
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Glucocorticoids are permitted both in and out of competition when administered by: inhalation (e.g., glucocorticosteroid inhalers) intranasal (e.g., nasal sprays for allergic rhinitis) ophthalmic (e.g., eye drops) perianal (e.g., topical hemorrhoid creams) dermal (e.g., topical creams to treat rashes or allergic reactions) dental intracanal application USADA strongly recommends you check your medication and route of administration on Global DRO
Specifically, we report the development of a glucagon-like peptide-1 (GLP-1)-estrogen conjugate that has superior sex-independent efficacy over either of the individual hormones alone to correct obesity, hyperglycemia and dyslipidemia in mice